Product Description
Huabo Biopharm Co., Ltd. is developing HB-0025 as a treatment for solid tumors. (Sourced from: http://www.huabobio.com/en/product.html)
Mechanisms of Action: PD-L1 Inhibitor,VEGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huabo Biopharm Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Endometrial Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HB0025-C-01 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Endometrial Cancer |
2025-10-31 |
|
HB0025-0101 | P2 |
Recruiting |
Kidney Cancer|Renal Cell Carcinoma |
2025-01-30 |
57% |
CTR20222862 | P2 |
Not yet recruiting |
Kidney Cancer |
None |
|
CTR20210604 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |